Mount Sinai Researchers Receive $13 Million NIH Grant to Study Connection Between Stress-Associated Brain Activity and Cardiovascular Risk
Project aims to provide new guidelines for clinicians and researchers to provide more comprehensive risk assessment in patients
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded $13 million from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) for a five-year research program that aims to uncover the mechanisms by which stress contributes to cardiovascular risk. The program aims to improve our understanding of how the effect of stress on the brain can directly impact the immune system and cardiovascular disease, and to provide a scientific platform for clinicians and researchers to integrate this knowledge into patient care.
While abundant epidemiological data exists describing severe chronic stress as a risk factor for cardiovascular disease, the mechanism by which stress contributes to cardiovascular events is not fully understood. Preclinical preliminary data from the program's investigators describe a direct causal link between psychosocial stress, neural signals, and atherosclerosis, the chronic inflammatory disease that is the underlying cause of heart attacks and strokes. To better characterize risk of future cardiovascular events as affected by psychosocial stress, researchers will study the levels of macrophages—key immune cells contributing to the inflammation that characterizes atherosclerosis—within the arteries, blood, and organs of the immune system.
The program consists of three distinct studies. The first will use mouse models to explore how the brain reacts to stress and affects the immune system to increase cardiovascular disease risk. The second study will translate discoveries from the first to develop non-invasive imaging methodologies, such as combined MRI and PET scans, in order to study these same processes in larger mammals and humans. The third study will then use these imaging technologies to examine the link between increased emotional stress and increased cardiovascular risk in human subjects diagnosed with post-traumatic stress disorder.
“A better understanding of non-traditional risk factors to cardiovascular disease, such as psychosocial stress, allows for a more comprehensive risk assessment in patients,” says Zahi A. Fayad, PhD, Mount Sinai Endowed Chair in Medical Imaging and Bioengineering, Professor of Radiology and Medicine (Cardiology), and Director of the Translational and Molecular Imaging Institute (TMII) at the Icahn School of Medicine at Mount Sinai, and the Principal Investigator of the study. “The development of non-invasive imaging technology to assess cardiovascular risk in relationship to brain and immune system activation opens new opportunities for early diagnosis and treatment of cardiovascular disease.”
“The findings from this pioneering study will have significant impact on current and future research in cardiovascular disease, psychiatry, and imaging,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. “We appreciate the NIH recognition of our efforts and are excited to be part of this groundbreaking endeavor.”
The research team from the Icahn School of Medicine at Mount Sinai is composed of Dr. Fayad (overall PI, PI Project 3 and Administration/data Core); Willem Mulder, PhD, Professor, (PI Project 2); Venkatesh Mani, PhD, Assistant Professor (PI Imaging Core); Cheuk Tang, PhD, Associate Professor; Claudia Calcagno, MD, PhD; James Murrough, MD, Assistant Professor; Dr. Charney; Valentin Fuster, MD, PhD, Director, Mount Sinai Heart; Emilia Bagiella, PhD, Professor; and Helena Chang, MS, Senior Biostatistician. Other institutions involved in this program include New York University and Massachusetts General Hospital. The research team includes multidisciplinary investigators in cardiac and neuroimaging, psychiatry, psychology, neuroscience, neurology, cardiology, immunology, and nanotechnology.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.